Greet­ings:National Institute of Biomedical Innovation

National Institute of Biomedical Innovation　Director, Research Institute　KATAGIRI Toyomasa

The National Institute of Biomedical Innovation is dedicated not only tofoundational drug discovery research essential for developing pharmaceuticals toovercome a wide range of diseases, but also to advancing studies on biologicalresources that support drug discovery, including nonhuman primates and medicinalplants.

To date, we have achieved significant progress: establishing an AI-driven drugdiscovery platform that accelerates patient stratification and target identification;releasing databases for rare and intractable diseases; developing infectious diseasemodels such as those for COVID‑19; and creating antibody, artificial nucleic acid,and peptide therapeutics, as well as innovative imaging systems for drug discovery.

Looking ahead, we will continue to strengthen and expand these foundationalcapabilities, promote next‑generation drug discovery for rare diseases, intractableconditions, and infectious diseases, and deepen collaboration across industry,government, and academia. Through these efforts, we aim to ensure that ourresearch outcomes are returned to society.

With the aspiration to serve as a cornerstone of future medicine, all members ofour institute remain committed to taking on new challenges. We sincerely ask foryour continued understanding and warm support.